PRODUCT INFORMATION



Bivalirudin

Item No. 23035

CAS Registry No.: 128270-60-0

Formal Name: D-phenylalanyl-L-prolyl-L-arginyl-

> L-prolylglycylglycylglycyl-L-asparaginylglycyl-L-α-aspartyl-L-phenylalanyl-L- α -glutamyl-L- α glutamyl-L-isoleucyl-L-prolyl-L-αglutamyl-L-α-glutamyl-L-tyrosyl-L-

leucine


 $C_{98}H_{138}N_{24}O_{33}$ 2,180.3 MF:

FW: ≥98% **Purity:**

UV/Vis.: λ_{max} : 278 nm A crystalline solid Supplied as:

-20°C Storage: Stability: ≥4 years

Information represents the product specifications. Batch specific analytical results are provided on each certificate of analysis.



Laboratory Procedures

Bivalirudin is supplied as a crystalline solid. A stock solution may be made by dissolving the bivalirudin in the solvent of choice. Bivalirudin is soluble in organic solvents such as DMSO and dimethyl formamide, which should be purged with an inert gas. The solubility of bivalirudin in these solvents is approximately 30 mg/ml.

Further dilutions of the stock solution into aqueous buffers or isotonic saline should be made prior to performing biological experiments. Ensure that the residual amount of organic solvent is insignificant, since organic solvents may have physiological effects at low concentrations. Organic solvent-free aqueous solutions of bivalirudin can be prepared by directly dissolving the crystalline solid in aqueous buffers. The solubility of bivalirudin in PBS (pH 7.2) is approximately 10 mg/ml. We do not recommend storing the aqueous solution for more than one day.

Description

Bivalirudin is an inhibitor of α - and ζ -thrombin (K_i s = 2.56 and 1.84 nM, respectively), enzymes that exhibit high fibrinogen-clotting activities. It is selective for α - and ζ -thrombin, lacking activity at trypsin and y-thrombin, which lacks clotting activity, at a >1,000-fold excess of bivalirudin. Bivalirudin inhibits α-thrombin-stimulated activation of the clotting factors Factor X, Factor V, and prothrombin in contact-activated plasma at a concentration of 0.1 µM.2 Administration of bivalirudin (0.5-1.5 mg/kg, i.v.) reduces platelet deposition in a rat carotid endarterectomy model in a dose-dependent manner.³ Formulations containing bivalirudin have been used to prevent ischemic events during angioplasty for thrombus-containing lesions.⁴

References

- 1. Witting, J.I., Bourdon, P., Brezniak, D.V., et al. Biochem J. 283(Pt 3), 737-743 (1992).
- 2. Ofosu, F.A., Fenton, J.W., II, Maraganore, J.M., et al. Biochem J. 283(Pt 3), 893-897 (1992).
- 3. Hamelink, J.K., Tang, D.B., Barr, C.F., et al. J. Vasc. Surg. 21(3), 492-498 (1995).
- 4. Shah, P.B., Ahmed, W.H., Ganz, P., et al. J. Am. Coll. Cardiol. 30(5), 1264-1269 (1997).

WARNING
THIS PRODUCT IS FOR RESEARCH ONLY - NOT FOR HUMAN OR VETERINARY DIAGNOSTIC OR THERAPEUTIC USE.

This material should be considered hazardous until further information becomes available. Do not ingest, inhale, get in eyes, on skin, or on clothing. Wash thoroughly after handling. Before use, the user must review the complete Safety Data Sheet, which has been sent via email to your institution.

Buyer agrees to purchase the material subject to Cayman's Terms and Conditions. Complete Terms and Conditions including Warranty and Limitation of Liability information can be found on our website.

Copyright Cayman Chemical Company, 10/25/2022

CAYMAN CHEMICAL

1180 EAST ELLSWORTH RD ANN ARBOR, MI 48108 · USA PHONE: [800] 364-9897

[734] 971-3335

FAX: [734] 971-3640 CUSTSERV@CAYMANCHEM.COM WWW.**CAYMANCHEM**.COM